AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03205397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Usual care
Study NCT02154464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02154464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04377685 — intervention group
Intervention type: OTHER
Intervention: CT-Scan
Description: Chest CT scan on admission to the hospital
Study NCT02124447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG+E
Description: Split dose 4 liter polyethylene glycol with electrolytes
Study NCT02124447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG+Asc
Description: Split dose 2 liter polyethylene glycol with ascorbic acid
Study NCT02124447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P+MC
Description: Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
Study NCT02124447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfate
Description: Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
Study NCT02888210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-15 Intraocular Lens
Study NCT03101150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU Vitamin D3
Description: Antenatal multivitamin
Study NCT03101150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000 IU Vitamin D3
Description: 4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
Study NCT01776554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine
Study NCT03618901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rock Steady Boxing
Description: Boxing programs as offered by the Rock Steady Boxing institution,
Study NCT03618901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD SAFEx
Description: Progressive proprioception training.
Study NCT03242369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
Study NCT03242369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
Study NCT03242369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
Study NCT03242369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: 100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
Study NCT02126280 — intervention group
Intervention type: OTHER
Intervention: In vitro estimation of individual reactivity of monocytes
Description: Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
Study NCT00563290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO
Study NCT00563290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04610229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation guioded by dose painting
Description: 1
Study NCT00922636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Taken in tablet form QD po.
Study NCT00922636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
Study NCT00922636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (tablet)
Description: Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
Study NCT00922636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (capsule)
Description: Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
Study NCT03834311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: isokinetic strengthening
Description: isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
Study NCT03834311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise band strengthening
Description: upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
Study NCT02359110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
Study NCT02359110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive placebo tab less than 1 hour before surgery
Study NCT01026025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duet TRS
Description: This is a single arm study.
Study NCT01561937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
Study NCT01561937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
Study NCT01561937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
Study NCT00738712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Magnetic Resonance Imaging
Description: MRI
Study NCT03110354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
Study NCT03278574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair
Description: Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
Study NCT03278574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Description: Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
Study NCT03278574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring annuloplasty with posterior band
Description: Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
Study NCT03278574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ring annuloplasty with complete ring
Description: Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
Study NCT03482050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstroRx
Description: Astrocytes derived from human embryonic stem cells
Study NCT01348126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
Study NCT01348126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of ganetespib and docetaxel
Description: Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
Study NCT04643132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
Study NCT04643132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine (low-dose)
Description: After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
Study NCT04643132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine (high-dose)
Description: After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
Study NCT01799759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
Study NCT01799759 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Completion of instruments only
Description: Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
Study NCT01092013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training on laparoscopic simulator in skills lab
Description: Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
Study NCT01092013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training at actual laparoscopic surgery
Description: Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
Study NCT01092013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical instruction
Description: Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
Study NCT04321928 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized health education
Description: Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
Study NCT04321928 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General health education
Description: Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
Study NCT02746835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program for fall prevention
Description: Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility.
Study NCT03316586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
Study NCT03316586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib may help to shrink or stabilize breast cancer
Study NCT01065753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Diet control with exercise
Study NCT03082508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl
Description: Algisyl device (implants) administered during a surgical procedure
Study NCT03082508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: as per protocol
Study NCT01037426 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fill out Questionnaire
Description: Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~* History of falls and fractures during the 12 months before pacemaker implantation~* Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~* History of falls and fractures during the 12 months after pacemaker implantation~* Medical and Arrhythmia History~* Cardiovascular Events~* Cardiovascular Medication~* Device programming information
Study NCT02536937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT01016743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial stimulation (r-TMS)
Description: Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin Hydrochloride
Description: Aldoxorubicin Hydrochloride HCI
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-\[HER2\]
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast
Study NCT03563157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: haNK™, NK-92 \[CD16.158V, ER IL-2\]
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: BAVENCIO® injection
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: XELODA® tablets
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: ERBITUX® injection
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide Capsules
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU; Fluorouracil Injection
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin Calcium
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: ELOXATIN® injection
Study NCT00228163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide (HMR1726)
Description: tablet, oral administration once daily.
Study NCT02309086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells transduced with Ad encoding NS3
Description: Patients will receive 3 different dosis of the vaccine via subcutaneous injection
Study NCT02696824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression
Description: This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach.
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: STIVARGA® tablets
Study NCT02402517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded snack
Study NCT02402517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small particle size pea flour
Description: Pulse extruded snack
Study NCT02402517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large particle size pea flour
Description: Pulse extruded snack
Study NCT02402517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil flour
Description: Pulse extruded snack
Study NCT03563157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: STIVARGA® tablets
Study NCT03563157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy
Study NCT02402517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navy bean flour
Description: Pulse extruded snack
Study NCT02402517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto bean flour
Description: Pulse extruded snack
Study NCT00004246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
Study NCT00004246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Days 1-5 for 7 weeks
Study NCT02814071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Description: Early enteral feeding as per description
Study NCT02558049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
Study NCT02824107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02824107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires for psychosocial factors
Study NCT05088772 — intervention group
Intervention type: DEVICE
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference.
Study NCT03944616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Beverage
Description: Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
Study NCT03944616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
Study NCT03535961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: apatinib+oral etoposide
Description: apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle